European Biotech Acquisition Corp.
Status: Deal Closed
U=S+W/3
W=S@11.50
| IPO Proceeds, $M | $127.55M |
|---|---|
| IPO Date | Mar 16, 2021 |
| CEO | Eduardo Bravo Fernandez de Araoz |
| Left Lead | Credit Suisse |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 24 months |
| IPO Sector |
Healthcare
Life Sciences Industry in Europe |
| IPO Geography | Europe |
| Target Company | Oculis |
| Deal Announced | Oct 17, 2022 |
| Deal Size, $M | $218.00M |
| Deal Sector | Healthcare |
| Deal Geography | Global |
| SEC Filings | www.sec.gov |
| Approval Vote | Feb 28, 2023 |
| Amendment Vote | TBD |
| Closing Date | Mar 2, 2023 |
Formerly EBAC
OCS
OCSAW
| Price | $15.28 |
|---|---|
| Last closing price | $15.29 |
| H/L, today | $15.19 / $15.61 |
| H/L, 52-week | $6.26 / $14.50 |
| Volume, today | 16,215 |
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on European Biotech Acquisition Corp.:
- Structure and cap table
- 6 directors & officers
- 17 filings and events
- 2 underwriters
- 8 deal advisors
- 5 legal advisors
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Eduardo Bravo Fernandez de Araoz | 55 | Chief Executive Officer |
| Koen Sintnicolaas | 32 | Chief Financial Officer |
| Martijn Kleijwegt | 66 | Director |
| Mark Wegter | 51 | Director |
| Volkert Doekson | 58 | Director |
| Onno van de Stolpe | 61 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
| Credit Suisse | Joint BR | 9,300,000 | units |
| Kempen & Co. | Joint BR | 2,700,000 | |
| 12,000,000 | units | ||
| Up-Front UW fee | 2.00 | % | |
| Deferred UW fee |
3.50 | % |
Sign in to view more advisor data.
Deal
Sign in to view merger details and deal financials.